Novartis AG ADR (NVS)vsCatheter Precision Inc. (VTAK)
NVS
Novartis AG ADR
$137.16
-0.23%
HEALTHCARE · Cap: $260.70B
VTAK
Catheter Precision Inc.
$0.18
+6.06%
HEALTHCARE · Cap: $758,350
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 2960370% more annual revenue ($56.69B vs $1.92M). NVS leads profitability with a 22.5% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
VTAK
Hold43
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-47.0%
Fair Value
$93.29
Current Price
$137.16
$43.87 premium
Intrinsic value data unavailable for VTAK.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Reasonable price relative to book value
Revenue surging 380.7% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bull Case : VTAK
The strongest argument for VTAK centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 380.7% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : VTAK
The primary concerns for VTAK are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
NVS profiles as a value stock while VTAK is a hypergrowth play — different risk/reward profiles.
NVS carries more volatility with a beta of 0.49 — expect wider price swings.
VTAK is growing revenue faster at 380.7% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 43/100), backed by strong 22.5% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Catheter Precision Inc.
HEALTHCARE · MEDICAL DEVICES · USA
Catheter Precision, Inc. develops and delivers electrophysiology products to provide patients, hospitals, and physicians with technologies and solutions to improve the lives of patients with cardiac arrhythmias in the United States. The company is headquartered in Fort Mill, South Carolina.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?